FDA’s workload estimates show the agency has been spending less time dealing with INDs, but with policy changes taking effect that will require more work with sponsors during that stage, that outlook should change.
Some of the agency time has shifted to NDAs and BLAs, as it faces more pressure to complete reviews faster.